Supplementary Material for: Systematic Review and Meta-Analysis of ­New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia Pan P. Wang L. Wang Y. Shen L. Zheng P. Bi C. Zhang A. Lv Y. Xue Z. Sun M. Sun C. Li J. Jin L. Yao Y. 10.6084/m9.figshare.9810527.v1 https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Systematic_Review_and_Meta-Analysis_of_New-Generation_Tyrosine_Kinase_Inhibitors_versus_Imatinib_for_Newly_Diagnosed_Chronic_Myeloid_Leukemia/9810527 <b><i>Backgrounds:</i></b> We performed this systematic review and meta-analysis to compare the efficacy of new-generation tyrosine kinase inhibitors (NG-TKIs; including dasatinib, nilotinib, bosutinib, radotinib, and ponatinib) versus imatinib for patients with newly diagnosed chronic myeloid leukemia (CML). <b><i>Summary:</i></b> We identified randomized controlled trials comparing the efficacy of NG-TKIs versus imatinib as the first-line treatment for CML patients by searching the PubMed, Cochrane library, and EMBASE databases. Two reviewers independently extracted data and assessed study quality. A meta-analysis was performed to calculate risk ratios and 95% CIs using a fixed-effects model.<b><i></i></b>Our study included 10 trials. Overall, treatment with NG-TKIs significantly improved the major molecular response and MR4.5 at all time points, and early molecular response at 3 months. Importantly, overall survival (OS) was significantly higher with the NG-TKIs at 12 months. Besides, NG-TKI-treated patients showed a significantly lower CML-related death and progression to the accelerated phase/blast crisis. <b><i>Key Messages:</i></b> In first-line treatment, NG-TKIs are superior to imatinib regarding OS at 12 months, and because molecular response rates were higher with the NG-TKIs at all time points, the NG-TKIs favor treatment-free remission. 2019-09-12 09:18:23 Chronic myeloid leukemia Tyrosine kinase inhibitor Imatinib Meta-analysis